申请人:Glaxo Group Limited
公开号:US04291059A1
公开(公告)日:1981-09-22
Compounds are disclosed of general formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom, a halogen atom or a group OR.sub.2, in which R.sub.2 represents a hydrogen atom, an alkyl group or an acyl group, R.sub.3 represents hydrogen or an alkyl, alkenyl or aryl group, R.sub.4 and R.sub.5 which may be the same or different, each represents a hydrogen atom or an alkyl, alkenyl or alkynyl group optionally substituted by an aryl or cycloalkyl group; or R.sub.4 and R.sub.5 together with the nitrogen atom may form a saturated four to seven membered ring, with the provisos that, when R.sub.4 and R.sub.5 simultaneously represent hydrogen atoms then (i) when R.sub.1 is hydrogen then R.sub.3 is not methyl and (ii) the compounds are the .beta.-isomers; and their physiologically acceptable salts. Compounds of formula (I) may be prepared from the corresponding .alpha.- or .beta.-configuration alcohols, from an aziridine intermediate or by a variety of alkylation procedures whereby the group R.sub.4 and/or R.sub.5 is introduced. The compounds (I) and their salts have analgesic activity and may be formulated as pharmaceutical compositions in conventional manner.
揭示了通式(I)的化合物:##STR1## 其中R.sub.1代表氢原子,卤素原子或OR.sub.2基团,其中R.sub.2代表氢原子,烷基或酰基,R.sub.3代表氢或烷基,烯基或芳基,R.sub.4和R.sub.5可能相同或不同,每个代表氢原子或烷基,烯基或炔基,可选地被芳基或环烷基取代;或者R.sub.4和R.sub.5与氮原子一起形成饱和的四至七元环,前提是当R.sub.4和R.sub.5同时表示氢原子时,当R.sub.1为氢时,R.sub.3不是甲基且化合物为.beta.-异构体;以及其生理上可接受的盐。通式(I)的化合物可以从相应的.alpha.-或.beta.-构型醇,从氮杂环中间体或通过各种烷基化过程制备,其中引入了基团R.sub.4和/或R.sub.5。化合物(I)及其盐具有镇痛活性,并可以按照常规方式制备为药物组成物。